近日,发表在PNAS上的“Tumorcell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance toPD-1 blockade therapy”文章,发现肿瘤细胞中同时表达PD-1和PD-L1,在缺乏适应性免疫的情况下,PD-1/PD-L1信号轴通过激活其主要的下游信号传导途径,包括AKT和ERK1/2途径,从而抑制肿瘤生长。发现PD-1信号...
这是一篇粉丝来稿,该文献是2021发表在《Nature communication》的《Single cell T cell landscape and T cell receptor repertoire profifiling of AML in context of PD-1 blockade therapy》,文章介绍了在经过PD-1免疫治疗前后AML(急性髓细胞性白血病)病人T亚群和占比的变化,提出可以使用免疫治疗前T细胞克隆型和GZMK...
[4]. Saleh R, ElkordE. Acquired resistance to cancer immunotherapy: Role of tumor-mediatedimmunosuppression[C]//Seminars in cancer biology. Academic Press, 2020, 65:13-27.[5]. Gong B, KiyotaniK, Sakata S, et al. Secreted PD-L1 variants mediate resistance to PD-L1blockade therapy in non...
PD-1 blockade therapyexhausted T cellneoantigensingle-cell RNA sequencingsingle-cell TCR sequencingtumor microenvironmenttumor-draining lymph nodetumor-specific T cellPD-1 blockade exerts clinical efficacy against various types of cancer by reinvigorating Tcells that directly attack tumor cells (tumor...
2023年6月7日，广州大学王雄军及中山大学刘炜共同通讯在Cellular & Molecular Immunology（IF=22）在线发表题为“Elevated nuclear PIGL disrupts the cMyc/BRD4 axis and improves PD-1 blockade therapy by dampening tumor immune evasion”的研究论文，该研究表明升高的核PIGL破坏cMyc/BRD4轴，并通过抑制肿瘤免疫...
Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy 今天跟大家分享日本庆应大学医学院去年3月发表在Elife上的一篇7.08分文章,探讨关于肿瘤对PD-1免疫治疗耐药的机制。 文章摘要:当前最热门的免疫治疗药物——靶向PD-1受体的抑制性抗体,其治疗原理是通过阻断癌细胞表面PD-1或...
通过单克隆抗体阻断PD-1介导的抑制性信号，可以在一定程度上逆转CD8+ T细胞耗竭，促进病毒清除或控制肿瘤进展，构成了PD-1免疫检查点阻断疗法（Immune checkpoint blockade, ICB）临床应用的基础。目前，尽管该疗法在系列癌症治疗中取得了较好的效果，但仍然面临很大的挑战：首先，一些恶性程度较高的癌肿，如胰腺癌、脑...
2023年8月12日,华中科技大学吴孔明、褚倩及梅齐共同通讯在Journal of Hematology & Oncology(IF=29)在线发表题为“Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy”的研究论文,该研究基于Nano-YBODY™技术平台开发了一种新型抗TGF-β/VEGF双特异性...
[2]Chamoto K,Hatae R,Honjo T. Current issues and perspectives in PD-1 blockade cancer immunotherapy[J]. Int J Clin Oncol,2020,25:790-800. [3]Hayashi H,Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibito...
[6].Iwai Y , Ishida M , Tanaka Y , et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.Proc Natl Acad Sci, 2002, 99(19):12293-12297 [7...